Epigenetic modulators, modifiers and mediators in cancer aetiology and progression

被引:613
|
作者
Feinberg, Andrew P. [1 ]
Koldobskiy, Michael A. [1 ]
Gondor, Anita [2 ]
机构
[1] Johns Hopkins Univ, Sch Med, Ctr Epigenet, 855 N Wolfe St,Rangos 570, Baltimore, MD 21205 USA
[2] Karolinska Inst, Dept Microbiol Tumour & Cell Biol, Nobels Vag 16, S-17177 Stockholm, Sweden
基金
美国国家卫生研究院;
关键词
HEMATOPOIETIC STEM-CELL; REPRESSIVE COMPLEX 2; EPITHELIAL-MESENCHYMAL TRANSITION; METHYLTRANSFERASE GENE EZH2; RECURRENT SOMATIC MUTATIONS; CHROMATIN REMODELING GENES; NUCLEAR-ENVELOPE PROTEIN; DNA METHYLATION; DRIVER MUTATIONS; SELF-RENEWAL;
D O I
10.1038/nrg.2016.13
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
This year is the tenth anniversary of the publication in this journal of a model suggesting the existence of 'tumour progenitor genes'. These genes are epigenetically disrupted at the earliest stages of malignancies, even before mutations, and thus cause altered differentiation throughout tumour evolution. The past decade of discovery in cancer epigenetics has revealed a number of similarities between cancer genes and stem cell reprogramming genes, widespread mutations in epigenetic regulators, and the part played by chromatin structure in cellular plasticity in both development and cancer. In the light of these discoveries, we suggest here a framework for cancer epigenetics involving three types of genes: 'epigenetic mediators', corresponding to the tumour progenitor genes suggested earlier; 'epigenetic modifiers' of the mediators, which are frequently mutated in cancer; and 'epigenetic modulators' upstream of the modifiers, which are responsive to changes in the cellular environment and often linked to the nuclear architecture. We suggest that this classification is helpful in framing new diagnostic and therapeutic approaches to cancer.
引用
收藏
页码:284 / 299
页数:16
相关论文
共 50 条
  • [1] Epigenetic modulators, modifiers and mediators in cancer aetiology and progression
    Andrew P. Feinberg
    Michael A. Koldobskiy
    Anita Göndör
    Nature Reviews Genetics, 2016, 17 : 284 - 299
  • [2] RETRACTED: Regulatory roles of epigenetic modulators, modifiers and mediators in lung cancer (Retracted Article)
    Shi, Lin
    Zheng, Minghuan
    Hou, Jiayuan
    Zhu, Bijun
    Wang, Xiangdong
    SEMINARS IN CANCER BIOLOGY, 2017, 42 : 4 - 12
  • [3] RETRACTION: "Regulatory roles of epigenetic modulators, modifiers and mediators in lung cancer" (Retraction of Vol 42, Pg 4, 2017)
    Shi, Lin
    Zheng, Minghuan
    Hou, Jiayuan
    Zhu, Bijun
    Wang, Xiangdong
    SEMINARS IN CANCER BIOLOGY, 2019, 54 : 183 - 183
  • [4] Editorial: Interplay between epigenetic modifiers and transcription factors in driving cancer progression
    Yang, Yongyong
    Di Ruscio, Annalisa
    Inoue, Satoshi
    Wang, Guocan
    Gao, Shuai
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [5] Epigenetic Modifiers in Cancer Metastasis
    Hu, Die
    Zhao, Tianci
    Xu, Chenxing
    Pan, Xinyi
    Zhou, Zhengyu
    Wang, Shengjie
    BIOMOLECULES, 2024, 14 (08)
  • [6] Targeting epigenetic modifiers in cancer
    Holloway, A. F.
    Oakford, P. C.
    CURRENT MEDICINAL CHEMISTRY, 2007, 14 (24) : 2540 - 2547
  • [7] Epimimetics: Novel Therapeutics Targeting Epigenetic Mediators and Modulators
    Hannan, Anthony J.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2020, 41 (04) : 232 - 235
  • [8] Epigenetic modulators of thyroid cancer
    Rodriguez-Rodero, Sandra
    Delgado-Alvarez, Elias
    Diaz-Naya, Lucia
    Martin Nieto, Alicia
    Menendez Torre, Edelmiro
    ENDOCRINOLOGIA DIABETES Y NUTRICION, 2017, 64 (01): : 44 - 56
  • [9] Targeting Epigenetic Modifiers for Cancer Treatments
    Chee C.S.
    Leung D.
    Current Pharmacology Reports, 2018, 4 (3) : 193 - 201
  • [10] RUNX Proteins as Epigenetic Modulators in Cancer
    Yi, Hongyang
    He, Yuhao
    Zhu, Qionghua
    Fang, Liang
    CELLS, 2022, 11 (22)